24.73 USD
↗ 0.15 (0.61%)AT CLOSE (11:59 AM EDT)
Bicara Therapeutics Inc. Common Stock
BCAXNASDAQ • USD
24.72
↘ 0.02 (0.06%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
24.72
↘ 0.02 (0.06%)
Market: CLOSED
Bicara Therapeutics Inc. Common Stock (BCAX) is currently trading at $24.70. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, BCAX trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Aug 26, 2026.
Open?$24.53
High?$24.87
Low?$24.03
Prev. Close?$24.58
Volume?423.8K
Avg. Volume?591.6K
VWAP?$24.57
Rel. Volume?0.72x
Bid / Ask
Bid?$14.00 × 100
Ask?$28.32 × 100
Spread?$14.32
Midpoint?$21.16
Valuation & Ratios
Market Cap?1.6B
Shares Out?66.2M
Float?50.7M
Float %?77.2%
P/E Ratio?N/A
P/B Ratio?3.49
EPS?-$2.80
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Themes
Address
116 HUNTINGTON AVENUE SUITE 703
BOSTON, MA 02116
Phone: 617-468-4219
BOSTON, MA 02116
Phone: 617-468-4219
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?23
Short Sent.?14
Piotroski F-Score?0/9Weak
Altman Z-Score?21.08Safe
Confidence?41%Low
Short InterestSqueeze Risk
Short % of Float?20.63%Squeeze Risk
Short Interest?10.5M
Days to Cover?13.3
Free Float50.7M
Avg Daily Volume787.8K
Settlement Date2026-08-14
Financial Health
Current Ratio?11.59Strong
Quick Ratio?11.59Strong
Cash Ratio?2.22Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?3.49FAIR▾
Peers100
S&P49
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-7.6CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-39.5%WEAK▾
S&P3
ROA?-36.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-135248000
Enterprise Value?$1.5B
Fundamentals ratios updated end of day